Current Oncology (Oct 2023)

Conversion in a Resectable Tumor after Denosumab Neoadjuvant in a Large Dorsal Giant Cells Tumor: A Case Report and a Literature Review

  • María Sereno,
  • Silvia Roa Franco,
  • Laura de la Reina,
  • José Luis Campo-Cañaveral de la Cruz,
  • Marta Muñoz de Legaría,
  • Enrique Casado Saénz

DOI
https://doi.org/10.3390/curroncol30100675
Journal volume & issue
Vol. 30, no. 10
pp. 9335 – 9345

Abstract

Read online

Giant cell tumors of bone are a rare entity, usually occurring in young patients and characteristically arising in the long bones. The spinal location is rare and usually presents with pain and/or neurological symptoms. The treatment of choice is surgery. Treatment with Denosumab, a bisphosphonate inhibitor of RANK-L, which is highly expressed in these tumors, has shown extensive activity in unresectable patients or those undergoing incomplete surgery. Preoperative treatment with this drug is gaining increasing interest, as its high potency in tumor reduction in this subtype of neoplasm has allowed resectability in selected patients. We present the case of a young patient with a large spinal tumor who, after neoadjuvant Denosumab, underwent complete en bloc surgery with clean margins and a great pathological response.

Keywords